We aim to uncover the role of non-genic regulatory elements and how their disruption drives cancer. Other than expanding our understanding of gene regulation and dysregulation in cancer, we aim to leverage this knowledge to predict novel therapeutic targets for the development of new drugs, and develop models to predict patient outcome to help guiding treatment plans for cancer patients.
Our approach combines cutting edge experimental techniques for epigenomic profiling of tumors and perturbation of cancer models with development of computational models and big-data analytical approaches.